Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bharat H. Barai who wrote (81)	3/4/1997 7:48:00 AM
From: NVestor	of 834

You stated that agatroban does everything that Heparin does but with fewer side effects but more costs. I was wondering if this would really be true, if the total cost of treating someone with heparin were taken into account. Specifically, how much does the cost of platelet monitoring add to the overall cost of treating someone with heparin. A news release some time ago mentioned that 3,000,000 people are exposed to heparin each year. If, on average, just one platelet count was eliminated per patient and, assumming the cost of that platelet count were $20 per test, a $60 million in savings per year on fewer platelet counts alone would result! Of course this money could be redirected to TXB which would result in approx $2.00 per share that could go to TXB shareholders! :) for a therapy that has fewer side effects. (even at $10 per test that is $1.00 per share... and I doubt that any medical test would be priced this low!) Under this scenario the TXB product would seem to be the clearly superior choice to heparin both in terms of cost and safety. Please let me know if there is some major flaw in my reasoning before I go out and buy more shares!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next